MedMen

MedMen registers as a private equity entity but does not operate a commingled fund. Its business model involves direct retail operation of three licensed cannabis dispensaries in California, selling flower, edibles, vapes, topicals, and wellness products. The firm occupies a hybrid space: it brands itself as an asset manager while functioning as a specialty retail operator.

MedMen previously pursued a multi-state retail footprint that included Nevada locations, but by 2026 the firm lists only three California storefronts. The retrenchment reflects the broader capital exodus from institutional cannabis after 2022, which forced many operators to sell assets, restructure, or close. Current public disclosures do not specify the timing or terms under which non-California locations were exited.

MedMen states it carefully sources products from licensed cannabis producers and subjects everything to safety and potency testing before sale. The firm does not publicly identify its supply-chain partners. Its model relies on aggregating branded and private-label products within a single retail experience rather than cultivating its own wholesale supply.

MedMen does not make fund commitments or take minority equity positions in cannabis startups. Its deployment history reflects a direct operating model rather than staged venture investment. Given the absence of disclosed fund vehicles or LP relationships, the concept of investment stages does not apply to the firm as currently structured.

There is no public evidence that MedMen commits capital to external funds or participates in co-investment vehicles. The firm's operations consist entirely of running its own dispensaries. This distinguishes it from cannabis-focused private equity firms that allocate to multiple portfolio companies through a fund structure.